Vivani Medical presented its obesity implant technology at the H.C. Wainwright 28th Annual Global Investment Conference on September 11, 2026. The proposed GLP-1 implant requires administration only once or twice per year. This delivery method aims to improve patient adherence and reduce side effects compared to current therapies.
Vivani confirmed that enrollment and dosing are complete for the SLIM-1 Phase I semaglutide implant study. Top-line data from the trial is anticipated in November 2026.
The company highlighted its ongoing technology partnership with Novo Nordisk. Preclinical animal models demonstrated sustained drug release and significant weight loss.